Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

EU: Bundesgerichtshof refers human stem cell patent case to ECJ (IPKat) (PatLit) (ipwars)

Global health policy – when is the price right? (Spicy IP)

Brazil gets closer to listing US IP retaliation targets (IP tango) (IP Watch)

Brazil: Patent office and health authorities – Office of the National General Attorney issues opinion stating on dual analysis system for pharmaceutical inventions (Koury Lopes Advogados)

EU: Bundesgerichtshof refers human stem cell patent case to ECJ (IPKat) (PatLit) (ipwars)

EU: MEP rejects calls for bar codes to stop fake drugs (Managing IP)

US: Interview with ACLU attorney Chris Hansen over gene patents (Patent Baristas)

US: The Coinco strategy – what can go wrong with ownership of patents within a corporate enterprise – Novartis Pharm. Corp. v. Teva Pharm. USA, Inc. (Property, intangible)

US: How do you solve a problem like Sidewiki (FDA Law Blog)

US: Bio Podcast: The role of patents in a pathway for the approval of biosimilars (Holman’s Biotech IP Blog)

US: Lilly files principal brief for Ariad v Lilly rehearing en banc – Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co. (Patent Docs) (ISinIP)

US: A brief defense of the written description requirement: Ariad v Lilly (Patently-O)

US: China food and drug outsourcing gets criminal. Fast. – US criminal liability for import of adulterated or misbranded food or drugs (China Law Blog)

US: Patent term adjustment: 37 CFR § 1.704(b)’s three-month provision (Patent Docs)

Amrix (Cyclobenzaprine) – US: Patent infringement suit commenced in response to Paragraph IV certification: Eurand Inc. et al. v. Teva Pharmaceuticals USA, Inc. et al (Patent Docs)

Carbatrol (Carbamazepine) – US: Settlement announced in patent dispute between Shire and Apotex over Carbatrol (Patent Docs)

Combigan (Brimonidine tartrate/Timolol maleate): US: Patent infringement suit following a Paragraph IV certification Allergan, Inc. v. Alcon Laboratories, Inc. et al. (Patent Docs)

Dovonex (Calcipotriol) – UK: EWHC dismisses Sandoz appeal against Floyd J’s finding that Leo Pharma’s patent was valid (PatLit)

Humira (Adalimumab): US: District Court E D Texas upholds record $1.7 billion infringement judgment: Centocor v Abbott (Patent Docs) (EDTexweblog.com)

Lexapro (Citalopram) – US: Infosint seeks increased damages award in Citalopram suit (Patent Docs)

Myfortic7 (Mycophenolate) – US: Patent infringement suit filed in response to Paragraph IV certification – Novartis AG et al. v. Apotex Inc. et al. (Patent Docs)

Prandimet (Repaglinide and Metformin) – US: Patent infringement suit filed in response to Paragraph IV certification: Novo Nordisk Inc. et al. v. Sandoz Inc (Patent Docs)

Roundup Ready soybean seed – US: Monsanto files patent infringement suit based on defendant’s use of seed produced from earlier planted Roundup Ready soybean seed: Monsanto Co. et al. v. Germann (Patent Docs)

Rozerem (Ramelteon) – US: Patent infringement suit filed in response to Paragraph IV certification: Takeda Pharmaceutical Co. Ltd. et al. v. Teva Pharmaceuticals USA Inc. et al. (Patent Docs)

Ryzolt (Tramadol) – US: Patent infringement suit filed in response to Paragraph IV certification: Purdue Pharma Products LP et al. v. Sun Pharmaceutical Industries Ltd. et al. (Patent Docs)

Zolpimist (Zolpidem) – US: Hi-Tech Pharmacal’s ECR subsidiary signs exclusive agreement to commercialise sleep aid in oral spray form (SmartBrief)